Lv2
114 积分 2026-08-10 加入
Altered gut microbial profile accompanied by abnormal short chain fatty acid metabolism exacerbates nonalcoholic fatty liver disease progression
33分钟前
已完结
Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma
10天前
已完结
Gut microbial enzymes and metabolic dysfunction-associated steatohepatitis: Function, mechanism, and therapeutic prospects
13天前
已完结
The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum
14天前
已完结
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
28天前
已完结
Semaglutide 7·2 mg: another step towards tackling diseases mediated by obesity
29天前
已完结
Probing the many benefits of GLP-1 receptor agonists
1个月前
已关闭
Probing the many benefits of GLP-1 receptor agonists
1个月前
已关闭
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
1个月前
已完结
GLP-1 analogue liraglutide attenuates CIH-induced cognitive deficits by inhibiting oxidative stress, neuroinflammation, and apoptosis via the Nrf2/HO-1 and MAPK/NF-κB signaling pathways
1个月前
已完结
皖公网安备34019202002308
